• Share
  • Email
  • Embed
  • Like
  • Save
  • Private Content

University of Maryland Baltimore

University of Maryland Baltimore
Experimental Therapeutics Symposium 2009



Total Views
Views on SlideShare
Embed Views



0 Embeds 0

No embeds


Upload Details

Uploaded via as Microsoft PowerPoint

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
Post Comment
Edit your comment

    Badros Badros Presentation Transcript

    • MM
      • 7/08-8/09
          • 124 MM
          • 14 Amyloidosis … 5 had heart TX, 2 kidney
          • 7 Waldenstrom Macroglobenemia
          • 3 POEMS
      • Acknowledge
          • Sunita Philip
          • Carolynn Harris
          • Amanda, Todd, Laurie, Donna
    • ONJ
      • Badros A, Terpos E, Katodritou E , Goloubeva O , Kastritis E, Verrou E, Zervas K, Baer MR, Meiller T , Dimopoulos MA. The natural history of osteonecrosis of the jaw in multiple myeloma patients.
        • J Clin Oncol 2008; 26: 5904-5909. Epub 2008 Nov 17.
      • Research Highlight; Nature Reviews Endocrinology 5, 184 (April 2009): Bone: Natural history of osteonecrosis of the jaw defined.
      • Featured work: The Myeloma Today, Fall 2009, Volume 7 Number 8
    • ONJ
        • Scheper MA, Badros A, Chaisuparat R, Cullen KJ, Meiller TF. Effect of zoledronic acid on oral fibroblasts and epithelial cells: a potential mechanism of bisphosphonate-associated osteonecrosis. Br J Haematol 2009; 144: 667-676. Epub 2008 Nov 20.
        • Scheper MA, Badros A, Salama AR, Warburton G, Cullen KJ, Weikel DS, Meiller TF. A novel bioassay model to determine clinically significant bisphosphonate levels. Support Care Cancer. 2009 Aug 4. [Epub ahead of print].
    • ONJ … What is next?
      • R-21 “GRANT10209881”.
          • Role of Salivary Bisphosphonates in Osteonecrosis of the Jaw in MM Patients.
      • Mutli-D clinic on Friday to study ONJ
          • Next year we will have an intervention to treat ONJ
    • IMF/MMRC - Collaboration
      • Richardson P, Jagannath S, Hussein M, Berenson J, Singhal S, Irwin D, Williams SF, Bensinger W, Badros AZ, Vescio R, Kenvin L, Yu Z, Olesnyckyj M, Zeldis J, Knight R, Anderson KC. T he safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple Myeloma. Blood 2009 May 26. [Epub ahead of print].
      • International Myeloma Working Group Collaborators. International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia 2009;23:215-224. Epub 2008 Nov 20.
      • International Myeloma Working Group Collaborators. The role of vertebral augmentation in multiple myeloma: International Myeloma Working Group Consensus Statement. Leukemia 2008; 22:1479-1484. Epub 2008 May 29.
    • Bortezomib & Vorinostat
      • Badros A, Burger AM, Philip S, Niesvizky R, Kolla SS, Goloubeva O, Harris C, Zweibel J, Wright JJ, Espinoza-Delgado I, Baer MR, Holleran JL, Egorin MJ, Grant S. Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma. Clin Cancer Res. 2009 Aug 15;15(16):5250-7. Epub 2009 Aug 11.
    • Bortezomib & Vorinostat
      • International Patent Application Number: PCT/US07/023211. Title: “Methods of Using SAHA and Bortezomib for Treating Multiple Myeloma” UMB Ref: AB-2007-025. Published by the World Intellectual Property Organization on May 15, 2009 # WO 2008/057456
      • Monograph: The Hematology Circle; Optimizing Epigenetic Therapy to Improve Outcomes. Based on a satellite Symposium Preceding the 50 th American Society of Hematology (ASH) meeting, December 5, 2008
      • A phase III trial is ongoing in 200 sites in the US and Europe to evaluate efficacy of the regimen
    • In Press … JCO
      • Phase I and pharmacologic study of SNS-032, a potent and selective Cdk2, 7 and 9 inhibitor, in patients with advanced chronic lymphocytic leukemia and multiple myeloma
      • Phase II Trial of weekly bortezomib in combination with rituximab in Relapsed or Relapsed/Refractory Waldenstrom’s Macroglobulinemia
    • ASH 2009
      • Phase I Study of Carfilzomib in Patients with Relapsed and Refractory Multiple Myeloma and Varying Degrees of Renal Insufficiency
      • Tanespimycin + Bortezomib in Relapsed/ Refractory MM Patients: Results From the Time-2 Study
    • On Going Work
      • AA in MM
        • Delayed access to SCT …
        • ??? Continue biological differences…
        • Pathology Dept, HLA markers
        • Access to Care with Amy Davidoff, ??? time or interest
      • SNP
        • pharmacogenomics in MM
            • Alan Schuldiner group.
        • Younger age and predisposition to MM in AA
            • Kevin Gardner at NIH “Biology & Gene expression laboratory”
    • On going/pending trials
      • CTEP
        • Vorinostat & Bortezomib in NHL With Steven Grant (open).
        • GDK-0449 after SCT in MM, “hedgehog pathway antagonist with JHH Bill Matsui (protocol pending)
        • 2 LOI’s in MM with Steven Grant.
      • Investigator Initiated
        • CDK inhibitors & Bortezomib with Cornell, Selena Chen.
        • Pomalidomide and Rituximab with DFCI, Steve Treon.
      • Industry sponsored
        • Arorakinase inhibitor (open)
        • CD-138 and ICAM Antibody trials (pending)
    • What is next?